

Study drugs: Samatasvir (IDX719) and IDX21437

Protocol number: IDX-04B-004

**A Multicenter, Randomized Study to Evaluate the Safety
and Efficacy of Samatasvir and IDX21437 Given in
Combination with or without Ribavirin in Subjects with
Chronic Hepatitis C Infection**

Author(s): Frank D, Zhou XJ, Sullivan-Bólyai JZ

Sponsor: Idenix Pharmaceuticals, Inc.
320 Bent Street
Cambridge, MA 02141

Eudract Number: 2014-001378-33

Document type: Protocol

Development phase: II

Version date: 08-May-2014

Property of Idenix Pharmaceuticals, Inc.
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Idenix Pharmaceuticals, Inc.

Table of contents

List of tables	6
List of abbreviations	7
Protocol synopsis	9
1 Background.....	14
1.1 Justification of selected doses.....	15
1.2 Risk/benefit assessment	15
1.2.1 Known Benefits.....	15
1.2.2 Potential Benefits	16
1.2.3 Known Risks	16
1.2.4 Potential Risks.....	16
1.2.5 Risk mitigation	17
1.2.6 Overall benefit/risk assessment.....	17
2 Study purpose	18
3 Objectives	18
3.1 Primary objectives	18
3.2 Secondary objectives	18
4 Study design	18
4.1 Data Safety Monitoring Board.....	19
4.2 Stopping rules	19
4.2.1 Study safety stopping rules	19
4.2.2 Futility rules (criteria for closing a treatment arm due to inadequate antiviral response)	20
4.2.3 Individual subject stopping rules	20
4.2.4 Virologic failure	21
5 Population.....	21
5.1 Inclusion/exclusion criteria.....	21
5.1.1 Inclusion criteria.....	21
5.1.2 Exclusion criteria	22
5.2 Premature subject withdrawal.....	25
6 Treatment.....	25
6.1 Subject numbering	25
6.2 Investigational and control drugs.....	26
6.3 Treatment arms	26
6.4 Treatment assignment.....	26
6.5 Treatment blinding	26